Although differential gene expression of tumor-infiltrating CD33 myeloid cells in advanced-versus early-stage CRC has been reported (Toor et al., 2021), it remains elusive whether there is a discrepant TME among CRC at TNM stage I/II. The gene discussed is CD33; the disease is colorectal carcinoma.